Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1

被引:28
作者
Bhatia, Smita [1 ]
Chen, Yanjun [1 ]
Wong, F. Lennie [2 ]
Hageman, Lindsey [1 ]
Smith, Kandice [1 ]
Korf, Bruce [1 ]
Cannon, Ashley [3 ]
Leidy, Daniel J. [3 ]
Paz, Alejandro [3 ]
Andress, Joseph E. [1 ]
Friedman, Gregory K. [1 ]
Metrock, Katie [4 ]
Neglia, Joseph P. [5 ]
Arnold, Michael [4 ]
Turcotte, Lucie M. [6 ]
de Blank, Peter [7 ]
Leisenring, Wendy [8 ]
Armstrong, Gregory T. [8 ]
Robison, Leslie L. [9 ]
Clapp, D. Wade [10 ]
Shannon, Kevin [10 ]
Nakamura, Jean L. [10 ]
Fisher, Michael J. [3 ]
机构
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[4] Univ Minnesota, Minneapolis, MN USA
[5] Nationwide Childrens Hosp, Columbus, OH USA
[6] Cincinnati Childrens Hosp, Cincinnati, OH USA
[7] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[8] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA
[9] Indiana Univ, Indianapolis, IN 46204 USA
[10] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
CHILDHOOD-CANCER SURVIVOR; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; CHILDREN;
D O I
10.1200/JCO.19.00114
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSEFundamental gaps in knowledge regarding the risk of subsequent neoplasms (SNs) in children with pathogenic neurofibromatosis type 1 (NF1) variants exposed to radiation and/or alkylator chemotherapy have limited the use of these agents.METHODSWe addressed these gaps by determining the SN risk in 167 NF1-affected versus 1,541 non?NF1-affected 5-year childhood cancer survivors from the Childhood Cancer Survivor Study and 176 nonoverlapping NF1-affected individuals with primary tumors from University of Alabama at Birmingham and Children?s Hospital of Philadelphia exposed to radiation and/or chemotherapy. Proportional subdistribution hazards multivariable regression analysis was used to examine risk factors, adjusting for type and age at primary tumor diagnosis and therapeutic exposures.RESULTSIn the Childhood Cancer Survivor Study cohort, the 20-year cumulative incidence of SNs in NF1 childhood cancer survivors was 7.3%, compared with 2.9% in the non-NF1 childhood cancer survivors (P = .003), yielding a 2.4-fold higher risk of SN (95% CI, 1.3 to 4.3; P = .005) in the NF1-affected individuals. In the University of Alabama at Birmingham and Children?s Hospital of Philadelphia cohort, among NF1-affected individuals with a primary tumor, the risk of SNs was 2.8-fold higher in patients with irradiated NF1 (95% CI, 1.3 to 6.0; P = .009). In contrast, the risk of SNs was not significantly elevated after exposure to alkylating agents (hazard ratio, 1.27; 95% CI, 0.3 to 3.0; P = .9).CONCLUSIONChildren with NF1 who develop a primary tumor are at increased risk of SN when compared with non-NF1 childhood cancer survivors. Among NF1-affected children with a primary tumor, therapeutic radiation, but not alkylating agents, confer an increased risk of SNs. These findings can inform evidence-based clinical management of primary tumors in NF1-affected children.
引用
收藏
页码:3050 / +
页数:10
相关论文
共 18 条
[1]   Occurrence of Multiple Subsequent Neoplasms in Long-Term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study [J].
Armstrong, Gregory T. ;
Liu, Wei ;
Leisenring, Wendy ;
Yasui, Yutaka ;
Hammond, Sue ;
Bhatia, Smita ;
Neglia, Joseph P. ;
Stovall, Marilyn ;
Srivastava, Deokumar ;
Robison, Leslie L. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) :3056-3064
[2]   Neuro-fibromatosis 1 and neuro-fibromatosis 2: a twenty first century perspective [J].
Ferner, Rosalie E. .
LANCET NEUROLOGY, 2007, 6 (04) :340-351
[3]   Subsequent Neoplasms in 5-Year Survivors of Childhood Cancer: The Childhood Cancer Survivor Study [J].
Friedman, Debra L. ;
Whitton, John ;
Leisenring, Wendy ;
Mertens, Ann C. ;
Hammond, Sue ;
Stovall, Marilyn ;
Donaldson, Sarah S. ;
Meadows, Anna T. ;
Robison, Leslie L. ;
Neglia, Joseph P. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (14) :1083-1095
[4]  
Grill J, 1999, ANN NEUROL, V45, P393, DOI 10.1002/1531-8249(199903)45:3<393::AID-ANA17>3.0.CO
[5]  
2-B
[6]   VONRECKLINGHAUSEN NEUROFIBROMATOSIS - A CLINICAL AND POPULATION STUDY IN SOUTHEAST WALES [J].
HUSON, SM ;
HARPER, PS ;
COMPSTON, DAS .
BRAIN, 1988, 111 :1355-1381
[7]   Advances in the treatment of neurofibromatosis-associated tumours [J].
Lin, Andrew L. ;
Gutmann, David H. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (11) :616-624
[8]  
Maris JM, 1997, CANCER-AM CANCER SOC, V79, P1438, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1438::AID-CNCR22>3.0.CO
[9]  
2-#
[10]  
MATSUI I, 1993, CANCER-AM CANCER SOC, V72, P2746, DOI 10.1002/1097-0142(19931101)72:9<2746::AID-CNCR2820720936>3.0.CO